CytomX Therapeutics (CTMX) EPS (Weighted Average and Diluted): 2019-2025
Historic EPS (Weighted Average and Diluted) for CytomX Therapeutics (CTMX) over the last 5 years, with Sep 2025 value amounting to -$0.09.
- CytomX Therapeutics' EPS (Weighted Average and Diluted) fell 228.57% to -$0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.48, marking a year-over-year increase of 182.35%. This contributed to the annual value of $0.38 for FY2024, which is 3900.00% up from last year.
- As of Q3 2025, CytomX Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.09, which was down 133.33% from $0.27 recorded in Q1 2025.
- Over the past 5 years, CytomX Therapeutics' EPS (Weighted Average and Diluted) peaked at $0.27 during Q1 2025, and registered a low of -$0.53 during Q4 2021.
- Its 3-year average for EPS (Weighted Average and Diluted) is $0.06, with a median of $0.03 in 2023.
- The largest annual percentage gain for CytomX Therapeutics' EPS (Weighted Average and Diluted) in the last 5 years was 2,200.00% (2024), contrasted with its biggest fall of 300.00% (2024).
- Quarterly analysis of 5 years shows CytomX Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.53 in 2021, then spiked by 75.47% to -$0.13 in 2022, then skyrocketed by 107.69% to $0.01 in 2023, then soared by 2,200.00% to $0.23 in 2024, then slumped by 228.57% to -$0.09 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.09 for Q3 2025, versus $0.27 for Q1 2025 and $0.23 for Q4 2024.